<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110058</url>
  </required_header>
  <id_info>
    <org_study_id>1954.00</org_study_id>
    <secondary_id>FHCRC-1954.00</secondary_id>
    <secondary_id>CDR0000423314</secondary_id>
    <nct_id>NCT00110058</nct_id>
  </id_info>
  <brief_title>Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Multi-Center Phase II Study of Nonmyeloablative Conditioning With TBI and Fludarabine for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Chronic Myeloid Leukemia in Chronic and Accelerated Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy&#xD;
      before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.&#xD;
      It also stops the patient's immune system from rejecting the donor's stem cells. The donated&#xD;
      stem cells may replace the patient's immune system and help destroy any remaining cancer&#xD;
      cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor&#xD;
      lymphocyte infusion) or interferon alfa after the transplant may help increase this effect.&#xD;
      Sometimes the transplanted cells from a donor can also make an immune response against the&#xD;
      body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may&#xD;
      stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving fludarabine together with radiation&#xD;
      therapy works in treating patients who are undergoing donor stem cell transplant for chronic&#xD;
      phase or accelerated phase chronic myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the disease-free survival rate in patients with chronic or accelerated phase&#xD;
           chronic myelogenous leukemia that failed or inadequately responded to prior imatinib&#xD;
           mesylate treated with nonmyeloablative conditioning comprising fludarabine and low-dose&#xD;
           total-body irradiation followed by allogeneic peripheral blood stem cell&#xD;
           transplantation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the complete cytogenetic and molecular response rates in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine non-relapse mortality in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of serious infection, graft-versus-host disease, and&#xD;
           myelosuppression in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Conditioning treatment: Patients receive fludarabine IV on days -4 to -2. Patients&#xD;
           undergo low-dose total-body irradiation (TBI) on day 0.&#xD;
&#xD;
        -  Allogeneic peripheral blood stem cell transplantation: After TBI, patients undergo&#xD;
           allogeneic peripheral blood stem cell transplantation on day 0.&#xD;
&#xD;
        -  Immunosuppression: Patients receive oral cyclosporine twice daily on days -3 to 56&#xD;
           followed by a taper to day 180 in the absence of graft-versus-host disease (GVHD).&#xD;
           Patients also receive oral mycophenolate mofetil twice daily on days 0-27.&#xD;
&#xD;
        -  Post-transplant treatment: Patients experiencing disease persistence or progression AND&#xD;
           low donor chimerism discontinue immunosuppression. Patients with disease persistence or&#xD;
           progression after discontinuing immunosuppression receive oral imatinib mesylate once&#xD;
           daily. Patients who have disease improvement after day 28 of imatinib mesylate treatment&#xD;
           AND who have no evidence of disease after day 84 of imatinib mesylate treatment continue&#xD;
           imatinib mesylate in the absence of disease progression or unacceptable toxicity.&#xD;
           Patients who fail to improve after day 28 of imatinib mesylate treatment OR who have&#xD;
           residual disease after day 84 of imatinib mesylate treatment receive donor lymphocytes&#xD;
           IV over 15-30 minutes once every 1-4 months for up to 4 infusions. Patients ineligible&#xD;
           to receive donor lymphocytes (e.g., patients with evidence of GVHD) receive interferon&#xD;
           alfa subcutaneously 3 times a week for up to 12 months in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 6, 9, 12, 18, and 24 months,&#xD;
      and then annually for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete molecular response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late nonrelapse mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of graft-vs-host disease (GVHD)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious infections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myelosuppression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival and disease-free survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia,&#xD;
             meeting 1 of the following criteria:&#xD;
&#xD;
               -  Chronic phase&#xD;
&#xD;
                    -  Ph+ by cytogenetics or fluorescent in situ hybridization (FISH) assay&#xD;
&#xD;
               -  Accelerated phase, meeting any of the following criteria:&#xD;
&#xD;
                    -  More than 10% but &lt; 30% myeloblasts and promyelocytes in marrow or&#xD;
                       peripheral blood&#xD;
&#xD;
                    -  Any additional clonal cytogenetic abnormalities&#xD;
&#xD;
                    -  Increasing splenomegaly&#xD;
&#xD;
                    -  Extramedullary tumor&#xD;
&#xD;
                    -  WBC, platelet count, or hematocrit perturbations not controlled by therapy&#xD;
                       with hydroxyurea, interferon, or imatinib mesylate&#xD;
&#xD;
                    -  Persistent unexplained fever or bone pain&#xD;
&#xD;
          -  Less than 5% blasts in the marrow at time of transplantation&#xD;
&#xD;
          -  Not eligible for OR refused conventional myeloablative allogeneic stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  Failed OR suboptimal response to prior imatinib mesylate, as defined by 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Absence of complete hematologic response after &gt; 3 months of treatment with&#xD;
                  imatinib mesylate&#xD;
&#xD;
               -  Absence of cytogenetic response, as defined by 1 of the following:&#xD;
&#xD;
                    -  Absence of any cytogenetic response (&lt; 95% Ph+ or BCR/ABL+ cells by&#xD;
                       cytogenetic or FISH analysis, respectively) after 6 months of treatment with&#xD;
                       imatinib mesylate&#xD;
&#xD;
                    -  Absence of major cytogenetic response (&lt; 35% Ph+ or BCR/ABL+ cells by&#xD;
                       cytogenetic or FISH analysis, respectively) after 1 year of treatment with&#xD;
                       imatinib mesylate&#xD;
&#xD;
                    -  Absence of complete cytogenetic response (no Ph+ cells by cytogenetic&#xD;
                       analysis OR BCR/ABL+ cells within normal limits by FISH analysis) after 18&#xD;
                       months of treatment with imatinib mesylate&#xD;
&#xD;
               -  Hematologic evidence of disease progression&#xD;
&#xD;
               -  Cytogenetic evidence of disease progression&#xD;
&#xD;
                    -  Increase in Ph+ cells or BCR/ABL+ cells by &gt; 20% with at least 1 month&#xD;
                       between sequential testing&#xD;
&#xD;
               -  Molecular evidence of disease progression&#xD;
&#xD;
                    -  More than 10-fold increase in BCR/ABL mRNA levels by quantitative polymerase&#xD;
                       chain reaction (Q-PCR) with at least 1 month between 2 sequential tests&#xD;
&#xD;
               -  Experienced adverse events during treatment with imatinib mesylate that precluded&#xD;
                  further administration of the drug&#xD;
&#xD;
          -  No CNS disease refractory to intrathecal chemotherapy&#xD;
&#xD;
          -  HLA identical related donor available&#xD;
&#xD;
               -  Phenotypically matched at HLA-A, -B, -C, DRQ1, and DBQ1&#xD;
&#xD;
          -  No presence of circulating leukemic blasts by standard pathology&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100% OR&#xD;
&#xD;
          -  Lansky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No fulminant liver failure&#xD;
&#xD;
          -  No cirrhosis of the liver with evidence of portal hypertension or bridging fibrosis&#xD;
&#xD;
          -  No alcoholic hepatitis&#xD;
&#xD;
          -  No esophageal varices&#xD;
&#xD;
          -  No history of bleeding esophageal varices&#xD;
&#xD;
          -  No hepatic encephalopathy&#xD;
&#xD;
          -  No uncorrectable hepatic synthetic dysfunction evidenced by prolongation of PT&#xD;
&#xD;
          -  No ascites related to portal hypertension&#xD;
&#xD;
          -  No bacterial or fungal liver abscess&#xD;
&#xD;
          -  No biliary obstruction&#xD;
&#xD;
          -  No chronic viral hepatitis AND bilirubin &gt; 3 mg/dL&#xD;
&#xD;
          -  No symptomatic biliary disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Renal failure allowed&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  Ejection fraction ≥ 35%&#xD;
&#xD;
          -  No other cardiac failure requiring therapy&#xD;
&#xD;
          -  No poorly controlled hypertension (blood pressure ≥ 150/90 mm Hg) on standard&#xD;
             medication&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO ≥ 30%&#xD;
&#xD;
          -  Total lung capacity ≥ 30%&#xD;
&#xD;
          -  FEV_1 ≥ 30%&#xD;
&#xD;
          -  No requirement for continuous supplementary oxygen&#xD;
&#xD;
          -  No fungal pneumonia with radiological progression after treatment with amphotericin or&#xD;
             mold-active azoles for &gt; 1 month&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 12 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other disease that severely limits life expectancy&#xD;
&#xD;
          -  No other active malignancy except localized nonmelanoma skin cancer&#xD;
&#xD;
          -  No nonhematologic malignancy within the past 5 years that is currently in complete&#xD;
             remission and has a &gt; 20% risk of disease recurrence except for nonmelanoma skin&#xD;
             cancer&#xD;
&#xD;
          -  No systemic uncontrolled infection&#xD;
&#xD;
          -  No active bacterial or fungal infection unresponsive to medical therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 48 hours since prior imatinib mesylate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Sandmaier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>November 15, 2011</last_update_submitted>
  <last_update_submitted_qc>November 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2011</last_update_posted>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

